Abstract
Familial Mediterranean fever (FMF) has been reported more frequently in patients presenting with Henoch–Schönlein purpura (HSP) than in the general population. But, there is no clear knowledge about MEFV mutations in patients with HSP. We investigated the prevalence of MEFV mutations in children with HSP and without FMF whether these mutations have any effect on the disease course or complications. A total of 76 children with HSP who had no typical symptoms of FMF were screened for the mutations in exon 2 and exon 10 of the MEFV gene. Eleven of 76 patients (14.4 %) were heterozygous (E148Q in 5, M694V in 4, M680I in 1, E148V in 1), 5 (6.6 %) were homozygous (M694V/M694V in 4, V726A/V726A in 1), and 2 (2.6 %) were compound heterozygous (E148Q/M694V mutations in 1 and L110P/E148Q mutations in 1). Altogether, 7 patients carried 2 mutated MEFV alleles (9.2 %), which was higher than that observed in the general Turkish population (1 %). No significant differences in joint, gastrointestinal, renal involvement, or subcutaneous edema, and also acute phase reactants including leukocyte count, erythrocyte sedimentation rate, and serum C-reactive protein concentration were found between the groups. The prevalence of the two allele-MEFV mutations in patients with HSP was found higher than that of the general population. However, it seems that MEFV gene mutations may not have any effect on the clinical presentation of HSP.
Similar content being viewed by others
Introduction
Familial Mediterranean fever (FMF) is an inherited autoinflammatory disease characterized by recurrent self-limited attacks of fever and serositis accompanied occasionally by rashes and arthritis [1]. FMF is caused by mutations in the MEFV gene, which is located on chromosome 16p13.3. The MEFV gene comprises 10 exons and encodes pyrin, a protein involved in the regulation of apoptosis and inflammation. Over 80 mutations have been identified so far. Four missense mutations (M680I, M694V, M694I, and V726A) in exon 10, together with E148Q in exon 2, account for the majority of FMF mutations in populations originating from areas around the eastern Mediterranean region [2]. The various combinations of MEFV mutations are largely associated with the phenotypic variability of the disease. The most serious complication of FMF is the development of renal amyloidosis, which may be the only manifestation of the disease [3–5].
A connection between MEFV mutations and vasculitis such as Henoch–Schönlein purpura (HSP), polyarteritis nodosa, and Behçet disease has been increasingly reported in recent years [6–8].
HSP is the most common systemic small-vessel vasculitis in childhood, involving the skin, gastrointestinal (GI) tract, joints, and kidney [9]. It was reported that HSP occurs in 7 % of Turkish patients with FMF. The patients with HSP may develop symptoms related to FMF years after the presentation of HSP [6]. Because FMF is common in the Mediterranean region, we investigated MEFV mutations in patients presenting with HSP without any typical FMF symptoms and whether these mutations have any effect on the disease course or complications.
Materials and methods
Clinical and laboratory data of 76 pediatric patients meeting the criteria of the international study group for the diagnosis of HSP [10], who were followed at our institution between September 2000 and October 2010, were analyzed retrospectively. Two patients with established diagnosis of FMF before the diagnosis of HSP were excluded from the study. No patient had a family history or suspected diagnosis of FMF. For the diagnosis of FMF, Livneh criteria were used [1].
In all patients, the symptoms and signs of skin, GI tract, joint, and renal involvement were recorded on admission or at follow-up. Cutaneous findings consisted of characteristic palpable purpura and subcutaneous edema. GI manifestations included bowel angina and GI bleeding defined as the presence of melena, hematochezia, or occult blood in the stool. All patients were followed for a minimum period of 6 months for renal involvement, which was classified as microscopic hematuria, mild proteinuria (<20 mg/m2/h) and/or hematuria, nephrotic range proteinuria, nephrotic syndrome, nephritic syndrome, and nephritic–nephrotic (mixed) syndrome according to the initial clinical presentation. White blood cell (WBC) count, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), stool blood analysis, and other laboratory parameters were determined by standard laboratory methods at the time of diagnosis. Blood samples for mutation analysis and informed consent from the parents of the children were obtained during follow-up visits. The patients were divided into two groups according to the presence of MEFV mutations as Group 1: patients without a mutation and group 2: MEFV mutation carriers (patients with mutations in at least one allele; heterozygous, homozygous, and compound heterozygous).
The study was approved by the local Ethics Committee.
Detection of the MEFV gene mutations
Each sample was screened for the mutations located in exon 2 and exon 10 of the MEFV gene by direct sequencing. Genomic DNA was extracted from ethylenediamine–tetraacetic acid—anticoagulated whole blood samples using Genomic DNA Purification Kit (Invitrogen, Carlsbad, CA, USA). Following selective amplification of exon 2 and exon 10 with specific primers (primer sequences available upon request), polymerase chain reaction (PCR) products were run in a 2 % agarose gel containing ethidium bromide and visualized under UV light by an imaging system (SynGene InGenius, Cambridge, UK). Then, sequencing was performed using the BigDye Terminator v3.1 Cycle Sequencing Kit and an ABI prism 3130 Genetic Analyzer (Applied-Biosystems, Foster City, CA, USA).
Statistical analysis
All statistical analyses were performed using Statistical Package for the Social Science for Windows 16.0 (SPSS, version 16). All data are expressed as median, mean ± standard deviation, or percentage. Mann–Whitney, Student’s t test, Fisher’s exact test, and Yates’ continuity correction test were used, and values of p < 0.05 were accepted as statistically significant.
Results
The patient population consisted of 76 children (46 boys, 30 girls). Mean age at the time of diagnosis was 7.9 ± 3.7 years (range, 1.5–17.9 years). Palpable purpura, arthritis, GI involvement, edema, and renal involvement were found in 100, 78.9, 35.5, 31.5, and 28.9 % of the patients, respectively. The clinical data of the patients are shown in Table 1.
Of 76 patients, 58 (76.3 %) had no MEFV mutations, 11 (14.4 %) were heterozygous, and 7 (9.2 %) had mutations in both alleles, 5 of whom were homozygous and the remaining 2 were compound heterozygous (Table 2). Altogether, 25 mutated alleles were found in 18 patients, showing that the mutated allele frequency is 0.16.
Mean age at diagnosis and sex distribution of the groups were similar. Joint, renal, GI involvement, subcutaneous edema, as well as leukocyte counts, ESR or serum CRP concentrations were also similar among the groups (Table 3). Mean follow-up time of four patients with renal involvement in group 2 was 2.6 ± 1.1 years (range: 1.4–4.2 years), all of whom were in complete remission at the time of study. Clinical and laboratory features of the patients with renal involvement are shown on Table 4. Two of 4 patients with M694 V homozygous mutation had arthritis, one had bowel angina, and one had nephrotic range proteinuria during vasculitis episode. Because the patient who developed nephrotic range proteinuria did not respond to steroid treatment, cyclosporine A was used for 2 years. Her treatment had finished at the time of study, and her renal functions were preserved without proteinuria. No patient developed FMF during the follow-up period.
Discussion
Recent publications have reported that the prevalence of MEFV gene mutations in children presenting with HSP was higher than that of the general population [11–13] and that MEFV gene mutations could affect clinical and laboratory findings of HSP [12, 13].
It was reported in a previous study that the carrier frequency of five common MEFV gene mutations in the general Turkish population was 20 % (3 % for M694V, 5 % for M680I, 2 % for V726A, 0 % for M694I, and 12 % for E148Q mutation) and that the mutated allele frequency was 0.11 [14]. In our study, mutated allele frequency was found to be 0.16. Although this ratio was higher than that of the general Turkish population, the association was not statistically significant (p = 0.11, Yates’ continuity correction test). However, we found that the frequency of homozygous and compound heterozygous MEFV mutations (9.2 %) was higher than that of the general Turkish population (1 %) (p = 0.026, Yates’ continuity correction test). Of these mutations, four were M694V/M694V, associated with a severe phenotype and amyloidosis, whereas two were V726A/V726A and E148Q/M694V, associated with a mild form of the disease, and the remaining one was L110P/E148Q, which is very rare in the Turkish population.
In a study from Turkey, Ozcakar et al. [12] found that 34 % of 80 patients with HSP had heterozygous MEFV mutations, whereas none of the patients had homozygous or compound heterozygous mutations. In another study from Turkey, Bayram et al. [13] demonstrated that heterozygous and homozygous/compound heterozygous mutation rates were 31 and 13 % in 107 patients, respectively. In a study from Israel, Gershoni-Baruch et al. [11] found that 27 % of 52 patients carried at least one mutation. In all three studies, the prevalence of MEFV mutations of patients with HSP was significantly higher than that of the general population, contrary to our study [11–13].
In the present study, subcutaneous edema existed in 50 % of mutation-positive patients. When mutation-positive and mutation-negative patients were compared, edema was more frequent in mutation-positive patients, although statistically insignificant (p = 0.054). Ozcakar et al. [12] found that edema was statistically more frequent in patients with heterozygous mutations in their study group. Bayram et al. [13] found that urogenital involvement was higher in mutation-positive patients; however, they found that the frequency of edema was not different between groups. The results from Israel [11] showed that there were no statistically significant differences in clinical manifestations between groups with and without mutations.
Overall prognosis of HSP is relatively good, and the long-term prognosis depends on renal involvement. The incidence of HSP nephritis (HSPN) has been reported to be 15–62 %, and end-stage renal disease occurs 1–7 % of HSPN patients [15, 16]. Having nephritic/nephrotic syndrome and/or more than 50 % of crescentic or sclerosing glomeruli are considered as the risk factors of long-term renal impairment [17, 18]. In our study, we did not find statistically significant correlation between MEFV mutation carriage and renal involvement. The lack of association may be explained by the small number of the patients.
In two studies from our country, it was reported that acute phase reactants were higher in the mutation carrier group [12, 13]. In our study, acute phase reactants including leukocyte counts, ESR, and serum CRP concentrations were not statistically different between the groups.
In conclusion, it seems that MEFV gene mutations may not affect the long-term prognosis and clinical presentation of HSP. However, further prospective studies are needed to confirm our results.
References
Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885
Touitou I (2001) The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 9:473–483
Mimouni A, Magal N, Stoffman N et al (2000) Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics 105(5):E70
Ben-Chetrit E, Backenroth R (2001) Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis 60:146–149
Kutlay S, Yilmaz E, Koytak ES, Tulunay OO, Keven K, Ozcan M, Ertürk S (2001) Case of familial Mediterranean fever with amyloidosis as the first manifestation. Am J Kidney Dis 38(6):E34
Ozdogan H, Arisoy N, Kasapçapur O et al (1997) Vasculitis in familial Mediterranean fever. J Rheumatol 24:323–327
Tekin M, Yalçinkaya F, Tümer N, Akar N, Misirlioğlu M, Cakar N (2000) Clinical, laboratory and molecular characteristics of children with Familial Mediterranean Fever-associated vasculitis. Acta Paediatr 89:177–182
Touitou I, Magne X, Molinari N et al (2000) MEFV mutations in Behçet’s disease. Hum Mutat 16:271–272
Saulsbury FT (2007) Clinical update: Henoch-Schönlein purpura. Lancet 24:976–978
Ozen S, Pistorio A, Iusan SM et al (2010) EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 69:798–806
Gershoni-Baruch R, Broza Y, Brik R (2003) Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schönlein purpura. J Pediatr 143:658–661
Ozçakar ZB, Yalçinkaya F, Cakar N et al (2008) MEFV mutations modify the clinical presentation of Henoch-Schönlein purpura. J Rheumatol 35:2427–2429
Bayram C, Demircin G, Erdoğan O, Bülbül M, Catlık A, Akyüz SG (2011) Prevalence of MEFV gene mutations and their clinical correlations in Turkish children with Henoch-Schönlein purpura. Acta Paediatr 100:745–749
Yilmaz E, Ozen S, Balci B et al (2001) Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 9:553–555
Mir S, Yavascan O, Mutlubas F, Yeniay B, Sonmez F (2007) Clinical outcome in children with Henoch-Schönlein nephritis. Pediatr Nephrol 22:64–70
Xia Y, Mao J, Chen Y et al (2011) Clinical outcomes in children with Henoch-Schönlein purpura nephritis grade IIIa or IIIb. Pediatr Nephrol 26:1083–1088
Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr Nephrol 12:238–243
Narchi H (2005) Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 90:916–920
Acknowledgments
The study was supported by a grant from the Scientific Research Fund of Akdeniz University.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dogan, C.S., Akman, S., Koyun, M. et al. Prevalence and significance of the MEFV gene mutations in childhood Henoch–Schönlein purpura without FMF symptoms. Rheumatol Int 33, 377–380 (2013). https://doi.org/10.1007/s00296-012-2400-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-012-2400-x